Intermediate
Workshop Session
Rebecca Martinez, MS, RN, FNP-C
Clinical Consultant
University of California, San Francisco/Clinician Consultation Center Substance Use Warmline
Hannah Snyder, MD
Assistant Clinical Professor
University of California San Francisco
Erin Lutes, MS, RN, PHN, CNS
Clinical Consultant
University of California, San Francisco
Elizabeth Gatewood, DNP, RN, FNP-C, RN, CNE
Associate Clinical Professor
University of California San Francisco
Jacqueline Tulsky, MD
Professor of Medicine, Emeritus/Faculty Consultant
UCSF/ Clinician Consultation Center-Substance Use Warmline
Triveni Defries, MD, MPH
Primary Care Addiction Medicine Fellow
University of California, San Francisco
Of the 70,237 drug overdoses in 2017, the majority were related to opioids. In response to the worsening opioid epidemic, the Department of Health and Human Services expanded buprenorphine prescribing privileges to include Nurse Practitioners and Physician Assistants and increased prescribing limits for physicians in 2016. However, even among physicians who already have DATA 2000 waivers, up to 40 percent have never prescribed buprenorphine. In order to increase access to this essential treatment for patients across the country, we must motivate waivered providers from all specialties to prescribe.
Research with physician prescribers has identified numerous barriers to buprenorphine prescribing including provider attitudes, payment issues, lack of education and lack of structural support. These barriers occur at patient, provider and systems levels. Case-based experiential learning can address these barriers and empower interdisciplinary clinicians to effectively provide buprenorphine.
In a 90 minute workshop, a multidisciplinary panel from the Substance Use Warmline will lead brief didactics and facilitate case reviews for three challenging scenarios in opioid use disorder management. Attendees will participate in small group case reviews of the following cases: 1) chronic pain and mental health 2) pregnancy and postpartum 3) polysubstance use. Groups will be guided to address patient, provider and systems level approaches to management for each case. Peer support resources and clinical tools will be discussed and shared as part of each case. Finally, the panel will review lessons learned in how to build a successful buprenorphine practice.